Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Comparison of a Monofocal eDOF IOL With a Monofocal IOL (MonoeDOF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04631068
Recruitment Status : Recruiting
First Posted : November 17, 2020
Last Update Posted : November 17, 2020
Sponsor:
Information provided by (Responsible Party):
Advanced Vision Science, Inc.

Brief Summary:

Post-market, prospective, randomized, single-masked, multi-center clinical study investigating the safety and effectiveness of the Monofocal Extended Depth of Focus Intraocular Lens (Mono-EDoF IOL) when compared to a Standard Monofocal Intraocular Lens.

Primary Objectives:

  • To evaluate the distance VA of the study IOLs
  • To evaluate the intermediate VA of the study IOLs
  • To explore the safety profile with regards to visual disturbances

Condition or disease Intervention/treatment Phase
Cataract Procedure: Cataract surgery Not Applicable

Detailed Description:

This study is aimed at patients who have a cloudy lens in both of their eyes, and are eligible for cataract surgery with implantation of an intraocular lens. Patients should be otherwise healthy with no other eye diseases.

The study will take place in 3 centers in Europe, including Oxford Eye Hospital, a part of Oxford University Hospitals NHS Trust and will include 70 patients in total.

The aim of the study is to investigate the safety and effectiveness of a new Intraocular Lens (IOL): the Monofocal Extended Depth of Focus (Mono-EDoF ME4) IOL and to compare it to a standard Monofocal IOL (TECNIS ZBC00). Patients participating will be randomised to either receive the Mono-EDoF ME4 IOL in both eyes or the TECNIS ZCB00 IOL in both eyes. Twice as many subjects will receive the Mono-EDoF ME4 IOL compared to the TECNIS ZCB00 IOL.

Both IOLs have received the CE marked. The aim with both IOLs is to provide patients good vision at distance with no glasses. The Mono-eDoF ME4 might offer the additional benefit of achieving good vision at intermediate distance without glasses.

Total duration of clinical investigation is 12 months and the total expected duration for each patient is 8 months.

Patients will be screened for eligibility preoperatively obtaining a medical history and to establish a baseline ocular condition. Surgeries will be performed on different dates for both eyes but not more than one month apart. The patient will need to return to for seven follow-up visits after eye surgery where vision and health of the eye will be assessed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Patients participating will be randomised to either receive the Mono-EDoF ME4 Intraocular Lens (IOL) in both eyes or the TECNIS ZCB00 IOL in both eyes. Twice as many subjects will receive the Mono-EDoF ME4 IOL compared to the TECNIS ZCB00 IOL.

Both IOLs have received the CE marked. The aim with both IOLs is to provide patients good vision at distance with no glasses. The Mono-eDoF ME4 might offer the additional benefit of achieving good vision at intermediate distance without glasses.

Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Multicentric Clinical Evaluation Comparing a Monofocal Extended Depth of Focus IOL With a Monofocal IOL
Actual Study Start Date : September 21, 2020
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Active Comparator: Santen xact Mono-EDoF ME4 Intraocular Lens (IOL)

The Monofocal Extended Depth of Focus (Mono-EDoF) posterior chamber foldable intraocular lens is ultraviolet and blue-light absorbing designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens. The diffractive technology of the IOL allows most of the light to converge in one focal point thereby providing high quality of distance vision and continuous focus to intermediate vision while minimizing the effects of unwanted visual disturbances. The visual quality is expected to be similar to monofocal IOLs.

Surgery to implant the Mono-EDoF ME4 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification.

Procedure: Cataract surgery
Small incision cataract surgery with implantation of an intraocular lens

Placebo Comparator: J&J TECNIS ZCB00 Intraocular Lens (IOL)

The TECNIS 1-Piece Intraocular Lens (IOL), Model ZCB00, is a standard monofocal ultraviolet light absorbing posterior chamber IOL, which is designed to be positioned in the lens capsule to replace the optical function of the natural crystalline lens.

Surgery to implant the TECNIS ZCB00 Intraocular Lens (IOL) will be performed on Day 0 of the study, using standard microsurgical techniques. All instruments and procedures used will be identical to those routinely used for small incision phacoemulsification.

Procedure: Cataract surgery
Small incision cataract surgery with implantation of an intraocular lens




Primary Outcome Measures :
  1. Monocular Uncorrected Distance VA at Visit 4 (Month 3) [ Time Frame: 80-100 days after second eye surgery ]
    Monocular uncorrected distance visual acuity measured using ETDRS visual acuity chart


Secondary Outcome Measures :
  1. Monocular Distance Corrected Intermediate VA at Visit 4 (Month 3) [ Time Frame: 80-100 days after second eye surgery ]
    Subject's vision is corrected for distance and then subject's intermediate vision is measured using a 66-cm ETDRS chart.

  2. Monocular Uncorrected Intermediate VA at Visit 4 (Month 3) [ Time Frame: 80-100 days after second eye surgery ]
    Intermediate Visual Acuity is measured using a 66-cm ETDRS chart.


Other Outcome Measures:
  1. Safety endpoints [ Time Frame: Baseline, Day 0 (Surgery), Visit 1 (Day 1), Visit 2 (Week 1), Visit 3 (Month 1), Visit 4 (Month 3), and Visit 5 (Month 6) ]
    The primary safety endpoint is the overall safety profile of the study IOLs as reflected by rates of adverse events.

  2. Safety endpoints [ Time Frame: Baseline, Visit 3 (Month 1), Visit 4 (Month 3), and Visit 5 (Month 6) ]
    The primary safety endpoint is the overall safety profile of the study IOLs as reflected by loss of BCDVA.

  3. Safety endpoints [ Time Frame: Baseline, Visit 1 (Day 1), Visit 2 (Week 1), Visit 3 (Month 1), Visit 4 (Month 3), and Visit 5 (Month 6) ]
    The primary safety endpoint is the overall safety profile of the study IOLs as reflected by slit lamp examination.

  4. Safety endpoints [ Time Frame: Baseline, Visit 5 (Month 6) ]
    The primary safety endpoint is the overall safety profile of the study IOLs as reflected by dilated fundus exam.

  5. Safety endpoints [ Time Frame: Baseline, Visit 1 (Day 1), Visit 2 (Week 1), Visit 3 (Month 1), Visit 4 (Month 3), and Visit 5 (Month 6) ]
    The primary safety endpoint is the overall safety profile of the study IOLs as reflected by intraocular pressure.

  6. Safety endpoints [ Time Frame: Day 0 (Surgery), Visit 1 (Day 1), Visit 2 (Week 1), Visit 3 (Month 1), Visit 4 (Month 3), and Visit 5 (Month 6) ]
    The primary safety endpoint is the overall safety profile of the study IOLs as reflected by device deficiencies.

  7. Safety endpoints [ Time Frame: Baseline, Day 0 (Surgery), Visit 1 (Day 1), Visit 2 (Week 1), Visit 3 (Month 1), Visit 4 (Month 3), and Visit 5 (Month 6) ]
    The primary safety endpoint is the overall safety profile of the study IOLs as reflected by visual symptoms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adults 22 years of age and older at the time of consent.
  2. Cataracts in both eyes.
  3. Expected post-operative refractive astigmatism of ≤ 1.0 D.
  4. Calculated lens power from 18 D to 30 D for both study IOLs.
  5. Willing and able to return for all scheduled treatment and post-operative visits for a minimum of 6 months.
  6. Planned removal of visually significant cataract (cortical, nuclear, posterior subcapsular, or a combination) by phacoemulsification cataract extraction in both eyes.
  7. Willing to discontinue contact lens wear, if applicable, and demonstrate corneal stability prior to biometry and surgery.
  8. Preoperative best corrected distance visual acuity (BCDVA) of 20/32 or worse, with or without a glare source, or preoperative BCDVA of 20/25 or worse with patient complaining of severe visual disturbances attributable to cataract.
  9. Post-operative BCVA projected to be 0.2 LogMAR or better (as determined by the medical judgment of the Investigator or measured by potential acuity meter / retinal acuity meter (PAM / RAM) if necessary).
  10. Pharmacologically dilated pupil size at least 6.0 mm.
  11. Must be able to understand and provide informed consent themselves or through a representative with a witness present on the IRB or EC approved Informed Consent Form (ICF).

Exclusion Criteria:

  1. Participation in any other drug or device clinical trial within 30 days prior to enrolling in this study and/or during study participation.
  2. Pregnancy or lactation.
  3. Subject who, in the clinical judgment of the Investigator, is not suitable for participation in the study for another clinical reason, as documented by the investigator (reason to be documented by the site on Case Report Forms - CRF's).
  4. Any type of cataract (e.g., traumatic, congenital, polar) other than those noted in inclusion criteria.
  5. History of any intraocular or corneal surgery in either eye (including LASIK, PRK, etc.).
  6. Ocular conditions which could affect the stability of the IOL (e.g., pseudoexfoliation, zonular dialysis, evident zonular weakness or dehiscence, etc.) in either eye.
  7. Any anterior segment pathology likely to increase the risk of complications from phacoemulsification cataract extraction (e.g., chronic uveitis, iritis, iridocyclitis, aniridia, rubeosis iridis, clinically significant corneal disease, Fuchs, or anterior membrane dystrophies, etc.) in either eye.
  8. Mature cataract that is likely to prolong phacoemulsification and/or lead to intraoperative complications prior to attempted IOL implantation.
  9. Any visually significant intraocular media opacity other than cataract in either eye.
  10. History of any clinically significant retinal pathology or ocular diagnosis (e.g., diabetic retinopathy, ischemic disease, macular degeneration, retinal detachment, amblyopia, optic neuropathy, microphthalmos, aniridia, etc.) in either eye that could alter or limit final postoperative visual prognosis.
  11. History of cystoid macular edema in either eye.
  12. Severe dry eye that, in the opinion of the investigator, would impair the ability to obtain reliable study measurements.
  13. Uncontrolled (e.g., non-medicated) glaucoma in either eye.
  14. Extremely shallow anterior chamber (< 2.0 mm).
  15. Subjects with large refractive errors (hyperopia/myopia) of axial or pathologic origin that, in the opinion of the investigator, could confound outcomes.
  16. Irregular astigmatism, corneal degeneration or dystrophy.
  17. Uncontrolled systemic disease (e.g., diabetes mellitus, active cancer treatment, mental illness, etc.) in the opinion of the Investigator, would put the subject's health at risk and/or prevent the subject from completing all study visits.
  18. Systemic medication that, in the opinion of the investigator, may confound the outcome or increase the intraoperative and post-operative risk to the subject (e.g., Tamsulosin Hydrochloride) or other medications including anticholinergics, alpha adrenergic blocking agents with similar side effects (e.g., small pupil/floppy iris syndrome).
  19. Subjects who may reasonably be expected to require any additional ophthalmic surgical intervention at any time during the study (other than YAG capsulotomy).
  20. Need for concomitant procedures (e.g., glaucoma surgery, RK, LASIK, etc.).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04631068


Contacts
Layout table for location contacts
Contact: Kristine A Morrill, BS +33(0)630016498 clinicals@medeuronet.com
Contact: Anne Roller, PhD +33388100410 aroller@medeuronet.com

Locations
Layout table for location information
France
University Hospital Pellegrin Recruiting
Bordeaux, Cedex, France, 33076
Contact: Charlotte Kalisky    +33 (0) 5 57 82 23 69    charlotte.kalisky@chu-bordeaux.fr   
Principal Investigator: Cedric Schweitzer, MD         
Sub-Investigator: David Toubol, MD         
Portugal
Hospital de Braga Recruiting
Braga, Portugal, 4710-243
Contact: Ana Sarmento    +351 925822081    ana.sarmento@ccabraga.org   
Principal Investigator: Tiago Monteiro, MD         
United Kingdom
Oxford Eye Hospital Not yet recruiting
Oxford, United Kingdom, OX3 9DU
Contact: Alexina Fantato    +44 (0)1865 231053    Alexina.Fantato@ouh.nhs.uk   
Principal Investigator: Paul Rosen, FRCOphth         
Sponsors and Collaborators
Advanced Vision Science, Inc.
Investigators
Layout table for investigator information
Study Chair: Mark Packer, MD Medical Monitor
Publications of Results:
Other Publications:
TECNIS Symfony DFU

Layout table for additonal information
Responsible Party: Advanced Vision Science, Inc.
ClinicalTrials.gov Identifier: NCT04631068    
Other Study ID Numbers: AVS CP-7944
First Posted: November 17, 2020    Key Record Dates
Last Update Posted: November 17, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cataract
Lens Diseases
Eye Diseases